Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Icecure Medical ( (ICCM) ).
On May 13, 2026, IceCure Medical announced that Nasdaq granted the company an additional 180-day period, until November 9, 2026, to regain compliance with the exchange’s $1.00 minimum bid price rule for its ordinary shares. The extension follows an initial 180-day window that expired on May 11, 2026, after IceCure’s share price had failed to meet the required threshold.
Nasdaq’s decision was based on IceCure meeting all other continued listing and initial listing standards, including market value of publicly held shares, and the company’s stated plan to cure the deficiency, potentially including a reverse share split if needed. The notice has no immediate impact on the listing or trading of IceCure’s shares, which will continue to trade on the Nasdaq Capital Market under the ticker ICCM, but it underscores ongoing pressure on the company to stabilize its share price to maintain long-term compliance.
The most recent analyst rating on (ICCM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
ICCM scores low overall primarily due to weak financial performance (large losses and significant cash burn despite modest revenue) and bearish technicals (below major moving averages with negative MACD). The latest earnings call adds meaningful upside from regulatory validation and stated commercial acceleration plans, but near-term execution and reimbursement timing risks keep the overall score constrained.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medical device company that develops and markets advanced liquid-nitrogen cryoablation therapy systems to destroy benign and cancerous tumors by freezing. Its minimally invasive ProSense system is sold globally, with a primary focus on breast, kidney, bone and lung cancers across markets including the U.S., Europe and Asia.
Average Trading Volume: 564,331
Technical Sentiment Signal: Sell
Current Market Cap: $16.49M
For detailed information about ICCM stock, go to TipRanks’ Stock Analysis page.